29.12.2015 • NewsElaine BurridgeDrug DevelopmentRecipharm

Recipharm in Ophthalmic Collaboration with Alcon

Swedish drug developer and toll manufacturer Recipharm has signed a long-term agreement with Swiss eye-care treatment company Alcon, part of Novartis, to manufacture a range of ophthalmic products using its Blow Fill Seal technology. Recipharm said the agreement will add annual sales of more than €36 million.

As part of the deal, Recipharm will also acquire full ownership of Kaysersberg Pharmaceuticals for €18 million, with 75% of the sum to be paid this year and the remaining 25% in January 2016. The acquisition, which is being financed with existing funds, is expected to close on Dec. 31.

Kaysersberg’s main asset is a manufacturing facility in Kaysersberg, France, which currently supplies the ophthalmic products. The 260 people working at the site will transfer to Recipharm.

Thomas Eldered, Recipharm’s CEO, said Blow Fill Seal was a very interesting and growing technology. The process is an injection-molding technique for producing plastic unit doses of sterile drugs.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.